Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

NCT03496519 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Contract Issues

Conditions

Solid Tumor, Adult

Interventions

DRUG: Dose Escalation of Durvalumab and Trabectedin
DRUG: Dose Expansion of Durvalumab and Trabectedin

Sponsor

University of Colorado, Denver